CI-980 in Advanced Melanoma and Hormone Refractory Prostate Cancer

被引：0
作者：
Christopher W. Ryan
Keith L. Shulman
Jon M. Richards
John W. Kugler
Jeffrey A. Sosman
Rafat H. Ansari
Everett E. Vokes
Nicholas J. Vogelzang
机构：
[1] University of Chicago,Department of Medicine, Section of Hematology/Oncology, Cancer Research Center
[2] University of Chicago Phase II Cooperative Network (Lutheran General Hospital,South Bend
[3] Peoria-Oncology/Hematology Associates,Michiana Hematology/Oncology, Decatur Memorial Hospital, Fort Wayne Medical Center
[4] University of Illinois,undefined
[5] University of Louisville,undefined
来源：
Investigational New Drugs | 2000年 / 18卷
关键词：
Malignant melanoma; prostate cancer; chemotherapy; clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Introduction: CI-980 is a novel chemotherapeutic agent thatinhibits polymerization of tubulin. Preclinical studies haveindicated a high level activity of this agent against various tumorcell lines. Methods: 13 malignant melanoma patients who hadfailed prior chemotherapy and/or immunotherapy and 13 hormonerefractory prostate cancer patients, including 4 who had receivedprior chemotherapy, were treated in 2 separate NCI-supportedclinical trials. Subjects received a recommended phase II dose ofCI-980 of 4.5 mg/m2/day by continuous infusion for 72 hoursevery 3 weeks. Results: No activity was seen in either study.Toxicity was tolerable with neutropenia being the most common,significant toxicity. Among the melanoma patients, 15% and 31%developed grade 3 and grade 4 neutropenia, while 7% and 38% ofthe prostate patients developed grade 3 and grade 4 neutropenia,respectively. Conclusions: CI-980 at this dose and scheduleis ineffective against malignant melanoma and hormone refractoryprostate cancer.
引用
收藏
页码：187 / 191
页数：4
相关论文
共 80 条
  • [1] Wheeler GP(1982)Inhibition of mitosis and anticancer activity against experimental neoplasms by ethyl 5-amino-1,3-dihydro-3-((N-methyl-anilino)methyl)-pyrido-(3,4-b)pryrazine-7-ylcarbamate (NSC 181928) Cancer Res 42 791-798
  • [2] Bowdon BJ(1983)Biological effects and structure-activity relationships of 1,2-dihydropyrido[3,4-b]pyrazines Cancer Res 43 3567-3575
  • [3] Werline JA(1994)Inhibition of microtubules and cell cycle arrest by a new 1-deaza-7,8-dlhydropteridine antitumor drug, Cl 980, and by its chiral isomer, NSC 613863 Cancer Res 54 75-84
  • [4] Wheeler GP(1987)Comparison of 1,2-dihydropyrido[3,4b]pyrazines (1-deaza-7,8-dihydropteridines) with several other inhibitors of mitosis Cancer Res 47 1621-1626
  • [5] Bowdon BJ(1990)Antitumor activity of ethyl 5-amino-1,2-dihydro2-methyl-3-phenyl-pyrido[3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice Cancer Res 50 3239-3244
  • [6] Temple CG(1997)A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors Invest New Drugs 15 235-246
  • [7] de Ines C(1992)Phase I clinical and pharmacokinetic trial of Cl980, a novel mitotic inhibitor Proc Am Soc Clin Oncol 11 292-407
  • [8] Leynadier D(1996)Phase I study of Cl 980 in patients with refractory malignancies Proc Annu Meet Assoc Cancer Res 37 Al 129-320
  • [9] Barasoain I(1997)Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent Clin Cancer Res 3 401-10
  • [10] Bowdon BJ(1998)CI-980 in renal cell and non-small cell lung cancer Cancer Therapeutics 1 318-576
12345678